NICE No For AZ's Tagrisso Highlights Flaws of England's New Cancer Drugs Fund

NICE, the HTA institute for England and Wales, has said a preliminary no to AstraZeneca PLC 's lung cancer drug Tagrisso (osimertinib). According to the firm, the decision shows that certain drugs will fare badly under NICE's new system for assessing cancer drugs.